慢性病防治专栏

四逆散合桂枝甘草龙骨牡蛎方治疗多囊卵巢综合征合并昼夜节律失调的临床效果

  • 常珍珍 ,
  • 王金权 ,
  • 成海红
展开
  • 1.山西白求恩医院,山西医学科学院生殖医学中心 (山西 太原 030032 )
    2.晋中市中医院妇科 (山西 晋中 030006 )

收稿日期: 2025-11-26

  网络出版日期: 2026-03-09

基金资助

国家中医药管理局全国名老中医专家传承工作室建设项目(国中医药人教函[2022]75号)

Clinical effect of Sini powder with Guizhi Gancao Longgu Muli decoction in the treatment of polycystic ovary syndrome with circadian rhythm disorder

  • Zhenzhen CHANG ,
  • Jinquan WANG ,
  • Haihong CHENG
Expand
  • 1.Reproductive Medicine Center,Shanxi Bethune Hospital (Shanxi Academy of Medical Sciences),Taiyuan 030032,Shanxi,China
    2.Department of Gynecology,Jinzhong Hospital of Traditional Chinese Medicine,Jinzhong 030006,Shanxi,China;Corrsponding author: CHANG Zhenzhen E?mail: 18235194129@163. com

Received date: 2025-11-26

  Online published: 2026-03-09

摘要

目的 观察四逆散合桂枝甘草龙骨牡蛎方治疗多囊卵巢综合征(PCOS)合并昼夜节律失调的临床效果。 方法 将2023年3月至2025年3月期间在山西白求恩医院就诊的102例PCOS合并昼夜节律失调患者采用随机数字表法分为观察组和对照组各51例,对照组给予达英-35及生活方式干预,观察组在对照组基础上予以四逆散合桂枝甘草龙骨牡蛎方加减,均连续治疗3个月经周期。比较两组临床疗效,治疗前后中医证候积分、内分泌激素、糖脂代谢指标、睡眠质量与节律指标变化,并记录不良反应。 结果 观察组总有效率(96.08%)高于对照组(80.39%)(P < 0.05);观察组治疗后中医证候积分、LH、LH/FSH比值、T、AMH、FBG、FINS、HOMA-IR、TG、TC、COR水平及PSQI评分均低于对照组(P < 0.05),FSH及褪黑素(MT)水平均高于对照组(P < 0.05);治疗期间,观察组与对照组不良反应发生率(3.92% vs. 5.88%)比较差异无统计学意义(P > 0.05)。 结论 四逆散合桂枝甘草龙骨牡蛎方可有效调节性激素紊乱,改善胰岛素抵抗与脂质代谢异常,重建正常的睡眠觉醒节律。

本文引用格式

常珍珍 , 王金权 , 成海红 . 四逆散合桂枝甘草龙骨牡蛎方治疗多囊卵巢综合征合并昼夜节律失调的临床效果[J]. 实用医学杂志, 2026 , 42(5) : 801 -806 . DOI: 10.3969/j.issn.1006-5725.2026.05.010

Abstract

Objective To observe the clinical efficacy of Sini powder combined with Guizhi Gancao Longgu Muli decoction in the treatment of polycystic ovary syndrome (PCOS) accompanied by circadian rhythm disorder. Methods A total of 102 patients diagnosed with PCOS and comorbid circadian rhythm disorder, who received treatment at Shanxi Bethune Hospital from March 2023 to March 2025, were randomly assigned to either an observation group or a control group using a random number table, with 51 cases in each group. The control group received Diane-35 along with lifestyle intervention, whereas the observation group was additionally treated with modified Sini powder combined with Guizhi Gancao Longgu Muli decoction. Both groups underwent treatment for three consecutive menstrual cycles. The clinical efficacy was compared between the two groups. Moreover, changes in traditional Chinese medicine syndrome scores, endocrine hormones, glucose and lipid metabolism indices, sleep quality, and circadian rhythm indicators were evaluated both before and after the treatment. Adverse reactions were also documented. Results The total effective rate in the observation group (96.08%) was significantly higher than that in the control group (80.39%) (P < 0.05). After treatment, the observation group showed lower scores of Traditional Chinese Medicine (TCM) syndromes, luteinizing hormone (LH), LH/follicle-stimulating hormone (FSH) ratio, testosterone (T), anti-Müllerian hormone (AMH), fasting blood glucose (FBG), fasting insulin (FINS), homeostasis model assessment of insulin resistance (HOMA-IR), triglyceride (TG), total cholesterol (TC), cortisol (COR), and Pittsburgh Sleep Quality Index (PSQI) scores compared to the control group (P < 0.05). In contrast, the levels of follicle-stimulating hormone (FSH) and melatonin (MT) were higher in the observation group than in the control group (P < 0.05). There was no statistically significant difference in the incidence of adverse reactions between the observation group (3.92%) and the control group (5.88%) (P > 0.05). Conclusion Sini powder combined with Guizhi Gancao Longgu Muli decoction can effectively regulate sex hormone disorders, improve insulin resistance and abnormal lipid metabolism, and restore the normal sleep-wake rhythm.

参考文献

[1] MATSUYAMA S, WHITESIDE S, LI S Y. Implantation and Decidualization in PCOS: Unraveling the Complexities of Pregnancy[J]. Int J Mol Sci, 2024, 25(2): 1203-1205. doi: 10.3390/ijms25021203 .
[2] PINTO J, CERA N, PIGNATELLI D. Psychological symptoms and brain activity alterations in women with PCOS and their relation to the reduced quality of life: A narrative review[J]. J Endocrinol Invest, 2024, 47(7): 1-22. doi: 10.1007/s40618-024-02329-y .
[3] AMIN S N, ASALI F, AOLYMAT I, et al. Comparing MitoQ10 and heat therapy: Evaluating mechanisms and therapeutic potential for polycystic ovary syndrome induced by circadian rhythm disruption[J]. Chronobiol Int, 2023, 40(8):1004-1027. doi: 10.1080/07420528.2023.2241902 .
[4] LAFCI N G, YILMAZ B, YILDIZ B O. PCOS - the many faces of a disorder in women and men[J]. J Endocrinol Invest, 2025, 48(4): 785-798. doi: 10.1007/s40618-024-02512-1 .
[5] SIDDIQUI S, MATEEN S, AHMAD R, et al. A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS)[J]. J Assist Reprod Genet, 2022, 39(11): 2439-2473. doi: 10.1007/s10815-022-02625-7 .
[6] WAHID S, RAMLI M D C, FAZLEEN N E, et al. Exploring the Therapeutic Potential of Natural Products in Polycystic Ovarian Syndrome (PCOS): A Mini-Review of Lipid Profile, Blood Glucose, and Ovarian Histological Improvements[J]. Life (Basel), 2024, 14(1): 150-153. doi: 10.3390/life14010150 .
[7] 李荔, 周嘉禾, 李末娟, 等. 多囊卵巢综合征表观遗传学、代谢组学、肠道菌群新机制前沿展望[J]. 实用医学杂志, 2022, 38(16): 1987-1992. doi:10.3969/j.issn.1006-5725.2022.16.001 .
[8] SHEN Z, YU M, DONG Z. Research Progress on the Pharmacodynamic Mechanisms of Sini Powder against Depression from the Perspective of the Central Nervous System[J]. Medicina (Kaunas), 2023, 59(4): 741-743. doi: 10.3390/medicina 59040741 .
[9] 中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵巢综合征中国诊疗指南[J]. 中华妇产科杂志, 2018, 53(1): 2-6. doi: 10.3760/cma.j.issn.0529-567x.2018.01.002 .
[10] SILVA G E, ROJO-WISSAR D M, QUAN S F, et al. Predictive ability of the International Classification of Sleep Disorders-3 in identifying risk of obstructive sleep apnea among recently unemployed adults[J]. Sleep Breath, 2021, 25(3): 1325-1334. doi: 10.1007/s11325-020-02210-1 .
[11] 国家中医药管理局. 中医病证诊断疗效标准[M]. 北京: 中国医药科技出版社, 2012: 122-124.
[12] SHRIVASTAVA S, CONIGLIARO R L. Polycystic Ovarian Syndrome[J]. Med Clin North Am, 2023, 107(2): 227-234. doi: 10.1016/j.mcna.2022.10.004 .
[13] 郭倩, 陈婕, 李晓欣, 等. 从子午流注学说探讨多囊卵巢综合征的治疗[J]. 南京中医药大学学报, 2024, 40(7): 661-667. doi: 10.14148/j.issn.1672-0482.2024.0661 .
[14] 周洁, 张慧丽, 王旭东. 理痰汤加味联合八段锦对多囊卵巢综合征胰岛素抵抗的影响[J]. 辽宁中医杂志, 2025, 52(8): 103-108. doi: 10.13192/j.issn.1000-1719.2025.08.026 .
[15] 孙六娜, 卢如玲, 张淑婷, 等. 寿胎丸对肾虚型多囊卵巢综合征不孕患者子宫内膜容受性及相关因子的影响[J]. 实用医学杂志, 2023, 39(3): 355-359. doi: 10.3969/j.issn.1006-5725. 2023.03.016 .
[16] 薄晓莉, 潘静, 冷静, 等. 石英毓麟汤加减对肾虚血瘀型多囊卵巢综合征患者免疫调控,抗缪勒管激素,促卵泡生成素水平的影响[J]. 中华中医药学刊, 2024, 42(5): 156-159. doi: 10.13193/j.issn.1673-7717.2024.05.031 .
[17] SALEHI S, ALLAHVERDY J, POURJAFAR H, et al. Gut Microbiota and Polycystic Ovary Syndrome (PCOS): Understanding the Pathogenesis and the Role of Probiotics as a Therapeutic Strategy[J]. Probiotics Antimicrob Proteins, 2024, 16(5): 1553-1565. doi: 10.1007/s12602-024-10223-5 .
[18] ZHU T, GOODARZI M O. Causes and Consequences of Polycystic Ovary Syndrome: Insights From Mendelian Randomization[J]. J Clin Endocrinol Metab, 2022, 107(3): 899-911. doi: 10.1210/clinem/dgab757 .
[19] NI F, WANG F, SUN J, et al. Proteome-wide Mendelian randomization and functional studies uncover therapeutic targets for polycystic ovarian syndrome[J]. Am J Hum Genet, 2024, 111(12): 2799-2813. doi: 10.1016/j.ajhg.2024.10.008 .
[20] ISMAIL A B, NAJI M S, NEBIH ?, et al. The expression profile of WNT/β-catanin signalling genes in human oocytes obtained from polycystic ovarian syndrome (PCOS) patients[J]. Zygote, 2022, 30(4): 536-542. doi: 10.1017/S0967199422000028 .
[21] VOROS C, ATHANASIOU D, PAPAPANAGIOTOU I, et al. Molecular Shadows of Per- and Polyfluoroalkyl Substances (PFASs): Unveiling the Impact of Perfluoroalkyl Substances on Ovarian Function, Polycystic Ovarian Syndrome (PCOS), and In Vitro Fertilization (IVF) Outcomes[J]. Int J Mol Sci, 2025, 26(14): 6604. doi: 10.3390/ijms26146604 .
文章导航

/